Introduction
Renal transplant is the preferred modality of treatment for end-stage renal disease (ESRD), as it is associated with lower morbidity and greater recipient survival [1] , improved quality of life [2] and lower medical expenses [3] compared to patients remaining on the transplant waiting list. However, since organ transplantation requires surgical intervention, aggressive immunosuppression, frequent blood sampling, patient monitoring and other diagnostic and therapeutic manoeuvres, it is associated with serious complications mostly attributed to therapy [4, 5] . In particular, immunosuppressive therapy, a core method required for successful transplantation, has a narrow therapeutic window. Insufficient immunosuppression might predispose recipients to acute organ rejection and shortened allograft survival, while there are complications attributed to overaggressive immunosuppression, such as serious infections [6] , malignancies [7] , gastrointestinal complications [8] , diabetes [9] and nephrotoxicity [10] and osteoporosis. An episode of acute rejection is one of the strongest predictors of decreased long-term allograft survival [11] . Since recipients at risk for acute rejection cannot be readily identified, an individulaized approach to immunosuppression therapy is challenging.
Identifying predictors of acute rejection and patients at risk may potentially change the therapy and be a step towards personalized medicine in transplantation in order to avoid rejection on one hand and serious side effects of over-immunosuppression on the other hand [12] . To date, environmental predictors (e.g. ischaemia-reperfusion injury [13] ), the degree of immunosuppression [14] and genetic [15] predictors for acute rejection have been postulated. Studying genetic factors associated with acute rejection may be complicated by several unanswered questions. First, is there enough evidence to hypothesize genetic predisposition to acute rejection? If so, what is the phenotype of interest? In other words, which forms of acute rejection are more likely to be associated with genetic factors?
Studying familial predisposition to acute rejection among transplant recipients may be an important step towards establishing the potential genetic component of acute rejection. The Utah Population Database (UPDB) is a unique resource of a population-based collection of genealogical information for the residents of the state of Utah. Using this resource might help to answer these questions and in addition, identify the target population, in the form of multiplex pedigrees where the rate of acute rejection is deviating from the expected.
The goal of this retrospective case-control study was to exploit the unique nature of the UPDB to evaluate if acute kidney transplant rejection or rejection-free survival aggregates in families. This might be viewed as an exploration to establish evidence for potential genetic predictors of acute renal transplant rejection.
Methods

Study design
This is a retrospective case-control study, where clinical information combined with genealogical data was used to evaluate the degree of familial aggregation in kidney transplant recipients whose course was complicated by acute rejection and also in those with rejection-free post-transplant course. There are some important differences in the design of this study compared to traditional case-control design. In this study, controls are the random samples from the full cohort with rejection status randomly assigned as described in greater details below. Patients with kidney transplant history who were followed at the University of Utah Solid Organ Transplant Program were enrolled in the study. No specific start date was defined for this study, so even recipients, who were transplanted as early as the 1960s were enrolled. Patients excluded from the study were paediatric patients (younger than 18), patients with primary non-functional graft, patients who had acute rejection identified in the explanted kidney and cases of acute rejection that coincided with BK virus infection in the same pathology specimen. Since BK virus was largely unknown until the late 1990s to diagnose BK nephropathy in our pathology specimen we used two criteria: (1) positive immunohistochemical staining for BK virus and (2) disproportionately high degree of interstitial inflammation (i3) with relatively mild tubulitis (t1); this criterion was mostly applied to earlier pathology reports.
Patients were followed for at least 1 year after transplantation; recipients who had a rejection episode within 1 year of transplantation were classified as 'early rejection' while those who had an acute rejection episode beyond 1 year were classified as 'late rejection'.
Utah Population Database
The UPDB is a research resource and rich source of information for genetic, epidemiological and public health studies. The central component of the UPDB is an extensive set of genealogical records extracted from the Family History Library, which is maintained by Church of Jesus Christ of Latter-day Saints (LDS or Mormons). These families represent the Utah pioneers and their descendants [16, 17] . The UPDB is actively creating new family histories and extending existing families from newly linked records; thus, family members are continually being added as the UPDB is linked to other sources of data, including statewide birth and death certificates [18] . Additional information on individuals within families comes from the Utah Cancer Registry, University of Utah Hospital Data Warehouse and other medical records that are linked to the UPDB. The UPDB includes approximately 7 million individual records, many of whom are linked into pedigrees. Here we have utilized data for the 2.5 million individuals in the resource with at least four generations of genealogical data.
The study was approved by the University of Utah Institutional Review Board (no. 12671).
Source of data
Demographic and medical data. The list of transplant recipients was compiled from the University of Utah Hospital Data Warehouse and the local database of the University of Utah Solid Organ Transplant Program. It was also supplemented by the data from the University of Utah Electronic Medical Record System and records from the Department of Pathology. The most recent clinic visit notes authored by one of the providers at the University of Utah Solid Organ Transplant Program were imported in the database. Finally, the missing information on the study participants was also requested from United Network for Organ Sharing (UNOS).
After combining these sources and eliminating redundant information, the study database was established, where each of the recipients was assigned a unique study ID number. The information regarding recipients' demographics, medical history and transplant procedure was retrieved from the resources available.
Pathology data. The biopsy reports from 1 January 1994 through 31 December 2006 were obtained from the University of Utah Hospital Data Warehouse. All pathology reports available to us were digitalized and imported in the study database. To select the patients with the outcome of interest, the data were queried first using appropriate key words for search (i.e. 'acute rejection', 'borderline rejection', 'tubulitis'). To increase the accuracy of the outcome, we reviewed the actual pathology reports to identify patients who indeed had acute rejection. To identify cases of acute rejection in recipients transplanted prior to 1994, and also in order not to miss patients who might have had transplantation or the biopsy and pathology evaluation performed in outside hospitals, we ran the search on the clinic visit notes and then reviewed the notes of the additional group of recipients who had a rejection mentioned in the clinic visit note but who did not have a pathology report.
Phenotype definition
Acute rejection was defined based on the retrospective results of the transplant kidney biopsy with some of the biopsy slides being reviewed by the pathologist (L.E., M.D.) specifically for the purpose of this study as described below. Only clinical rejection was considered a phenotype of interest as described elsewhere [15] . Generally, the diagnosis of clinical rejection at the time of biopsy required an inflammatory score of 4 or greater on the biopsy and ≥10% elevation in serum from the preceding 2 weeks in post-transplant months 1 to 3, or from the preceding month in months 3-12 [14, 15] . While protocol biopsies were not performed in this study, we also defined subclinical rejections based on the biopsies performed for indications other than elevated creatinine level. Subclinical rejection (not a part of the primary phenotype of interest for this study) was defined as an acute inflammatory score of 4 or greater on the biopsy, and an increase in the creatinine level <10% from baseline [15] . None of the subclinical rejections were identified in this study. However, in some cases the creatinine criteria were not available and the diagnosis was based solely on the biopsy report or clinic progress note. In addition, in a small number of cases, a biopsy was not obtained, but rejection was strongly suspected and treated empirically with serum creatinine concentrations promptly returning to the previous baseline following therapy with high-dose steroids. Those cases were also included in the phenotype. Finally, retrospective pathology cases, where reports did not clearly define grade of acute rejection, were reviewed again by the pathologist and graded based on the Banff 1997 classification [19] .
Statistical analysis
Descriptive statistics. The baseline characteristics were summarized by means and standard deviations for the continuous variables and by the percent of total for the categorical variables. The comparison between the recipients with and without acute rejection was performed by the t-test for continuous variables and by the chi-square test for the categorical variables.
Familiality analysis. To evaluate the familial aggregation of cases, we use the genealogical index of familiality (GIF) that was described elsewhere [20, 21] . Briefly, the GIF compares the average relatedness, summarized by the mean kinship coefficient [22] , of a set of individuals affected with some condition (cases) to the distribution of relatedness among multiple sets of controls drawn from the same population. The kinship coefficient (f) is calculated by using the following expression: [23] , where P i,j is the total number of paths of relationship between individuals i and j, and l(p) is the length in reproductive events of each path p. GIF is calculated for the group as (f · 100,000) wheref is the mean kinship over all pairs of individuals. In other words, the average kinship coefficient of cases (GIF) is calculated and compared to the mean of the kinship coefficients from the control population. The distribution of the control kinship coefficients is derived by repeatedly randomly sampling the control population. GIF is a robust, nonparametric test for familial aggregation of a disease.
Selection of the control population is a critical issue in calculating the GIF. Because only those who received transplants can experience acute rejection and the set of people receiving transplants is very likely to already exhibit familial clustering of the diseases for which transplant is indicated, we selected controls from only those patients who received a transplant. We then compared the mean kinship among rejection cases to the distribution of mean kinship among repeated samples of the controls, shuffling affection status (i.e. acute rejection) among subjects so that the marginal distribution of cases and non-cases remained the same, but family relationships were scrambled. In addition, we also calculated GIF for the randomly selected non-transplant subjects.
Subgroup analysis. Based on the fact that acute borderline rejection might have different clinical implications compared to the acute rejection grade 1A and above, we performed an additional subgroup analysis of the subjects with borderline rejection and those with acute rejection of grade 1A or above. In addition, since early acute rejections (within 1 year after transplant) could be explained by different mechanisms than late rejections (beyond first post-transplant year), recipients with early and late rejection episodes were analysed separately.
Results
Baseline characteristics
Out of 1909 recipients who were followed at the University of Utah, a total of 891 recipients with genealogical data (the presence of at least a child or a parent in the database) were identified in the UPDB. Of all patients enrolled in the study, 145 (16.1%) had acute rejection described by the Banff classification [19] as at least borderline. In 27 patients, the pathology report was not available and the information regarding rejection episode was derived from the clinic notes. Those cases were included in the acute rejection group, but not in the subgroup of acute rejection grade 1A or higher. In recipients with pathology reports, 77 recipients had biopsy-proven rejection grade 1A or higher. In three of the recipients, antibody-mediated rejection was identified, while the rest were diagnosed with cellular rejection. Subjects were 36.8 ± 16.7 years old and 40.9% were female. White recipients represented 87.2% of the study population while 0.9% of the population was African American (reflecting Utah general population trends).
The differences between recipients with and without history of rejection were as follows: recipients with a history of rejection were significantly younger, had a lower rate of diabetic nephropathy, lower degree of HLA match and were different in their immunosuppressive medication regimen as further described in Table 1 . We also evaluated the distribution of the HLA antigens in the donors and recipients in the cases and controls using chi-square analysis and found no significant differences.
We included all patients that we could identify; however, the proportion of those transplanted in the 1960s and 1970s was relatively small (10 patients were transplanted in the 1960s and 95 in the 1970s). Other baseline characteristics of the study population are presented in Table 1 .
Familiality analysis
The GIF statistic was computed for the 10 440 possible pairs of cases and compared to a permutation distribution generated by randomly assigning rejection status to 145 of the 891 subjects, representing the control group. In other words, the control group for the recipients with rejection and recipients without rejection was sampled from the group of all transplant recipients independent of their rejection status. Table 2 demonstrates that the transplants and all groups of rejection cases and non-cases have very similar distributions, with the possible exception of the acute rejection of grade 1A or higher.
After 100 permutations, the distribution of random GIF (control group, recipients with random assignment of rejection status) ranged from 0.31 to 12.0 with a median of 1.38 and a mean of 2.09 ( Table 2 ). The actual observed GIF among all cases of rejection was 1.53, which indicated the absence of familial clustering of acute rejection in the entire study population. Similarly, when the subgroup of recipients with early rejection was analysed (n = 52), we did not find any evidence of familial clustering indicated by a GIF of 0.18 compared to GIF 2.7 in controls. On the other hand, when the subgroup of recipients with acute rejection of grade 1A or higher (n = 77) was analysed separately, we observed a trend towards increased familial clustering (GIF = 3.02) compared to controls (GIF = 1.96); however, the P-value did not reach the level of statistical significance (P = 0.17) possibly due to relatively small sample size. We also observed a statistically significant increase in familial clustering in recipients who had a rejection-free course (GIF = 2.45) as compared to controls (GIF = 2.08, P = 0.04). Finally, when all transplant recipients were compared to non-transplant controls, they demonstrated a much greater degree of familiality (GIF = 2.03 versus GIF 0.63, P < 0.001). The trend that the transplants are very different from the non-transplant controls demonstrates that the test is sensitive to the familial aggregation of transplant.
Pedigrees
Looking for additional evidence of genetic components of the acute allograft rejection, we examined pedigrees of the renal transplant recipients. Several pedigrees with clusters of kidney transplantation and acute allograft rejection were identified in this project; a few examples are presented in Figures 1-3 . Two pedigrees demonstrated in Figure 1 represent the families, where acute rejection in transplant recipients is virtually absent. In the pedigrees represented in Figure 2 , the incidence of acute rejection among transplant recipients is 30% (panel on the left) and 60% (panel on the right). Finally in two pedigrees represented in Figure 3 , all those who received a kidney transplant had an episode of rejection except for one recipient. a Genealogical index of familiality is explained in the text; it compares the average relatedness (mean kinship coefficient) of a set of cases to the distribution of relatedness among multiple sets of controls drawn from the same population. b The P-values are arrived at by the location of the case GIF in the distribution of means from the repeated control samples.
Discussion
Acute rejection is the most significant predictor of longterm allograft survival; therefore, the prediction of acute rejection itself represents an important clinical issue. Though the incidence of acute rejection has been steadily declining over the last two decades, the clinical significance of this event is still very high. One might imagine that the large fraction of chronic allograft nephropathy is caused by slow, subclinical unrecognized acute rejection. In that regard, studying the causes and predictors of acute rejection, such as familial and possibly genetic predisposition, is very important to risk stratify the recipients and identify those with greater risk. Environmental predictors of acute rejections have been thoroughly evaluated. However, as we indicated before [24] , no definite genetic predictors have been identified, despite efforts to study candidate genes with most biologic plausibility. Genotypes for tumour necrosis factor (TNF)-alpha, interleukin (IL)-2, -6 and -10, interferon (IFN)-gamma and transforming growth factor (TGF)-beta-1 have been proposed in several studies to be associated with acute rejection [25] . However, there have also been several null results studying the same group of cytokines [26] . The controversy in the literature is further complicated by the fact that specific polymorphisms seemingly affect rejection risk differently in different settings. In particular, the combination of TNF-308A and IL-10-1082A alleles was associated with increased risk of acute rejection in heart transplantation [27] , but with decreased risk in kidney transplantation [28] .
In this project, we used a unique and powerful resource of the UPDB to establish evidence for familial aggregation of acute rejection, or, alternatively, for rejection-free survival. This study was undertaken to answer the question if there is indeed enough evidence to hypothesize the genetic predisposition to acute rejection. Increased familial aggregation of recipients with acute rejection or rejection-free survival might be direct evidence for genetic determinants of acute rejection. Finally, we tried to identify specific families in Utah that might be candidates for the future genetic study. We studied ∼900 patients with kidney transplantation performed, or followed at the University of Utah. These patients were identified in the Utah Population Database and had genealogical information that was used to evaluate the familial aggregation of the acute rejection or rejection-free post-transplant course. Patients with acute clinical rejection of all Banff grades starting with borderline were included in the study. In addition, we performed subgroup analysis where recipients with acute rejection of grade 1A or higher and those with relatively early onset of acute rejection (during the first post-transplant year) were studied separately. While we did not show any significant familial aggregation in the entire study group, there was a trend to increased familiality among recipients with acute rejection of grade 1A or higher. This trend did not reach the level of statistical significance probably due to the relatively small sample size, as only 77 patients were included in this subgroup. Interestingly, patients without a history of acute rejection (n = 746) during their post-transplant follow-up period had a significantly greater degree of familial aggregation compared to controls. Finally, as a proof of the reliability of the method, transplant recipients were found to have a significantly greater degree of familiality compared to nontransplant controls, indicating that the test is sensitive to the familial aggregation of transplant.
The important message of this study is that acute rejection of grade 1A or higher may have a trend for familial aggregation. On the other hand, there was a significantly greater degree of familiality in those who did not have rejection compared to controls. This finding might have a direct implication for the potential future genetic studies, where the genetic component of acute rejection or immune tolerance might be a subject of investigation. The present study would argue that, while searching for genetic determinants of acute rejection, the yield might be greater if the study population is limited only to those with acute rejection of Banff grade 1A or higher. Another important question that this study raises is whether borderline rejection has a different physiologic mechanisms compared to acute rejection of grade 1A or higher. It is possible that, while acute rejection of grade 1A or higher might have a degree of familial predisposition, borderline rejection may be a phenomenon caused by purely environmental factors.
In addition, it may be useful to identify pedigrees that had a number of rejection episodes either greater or lower than the acute rejection prevalence (10-20% [29] [30] [31] ). The families identified in this project may be a target of future genetic studies. While in this project we did not examine the familial aggregation of other transplant outcomes (e.g. adverse events related to immunosuppressive therapy due to over-immunosuppression), we consider it a potential topic of the follow-up studies.
Certain limitations of this study should be mentioned. The most important limiting factor of this study is its sample size. While we were able to identify almost 900 kidney transplant recipients at the University of Utah with the genealogical information available in the UPDB, the sample size of 145 acute rejection cases might be inadequate to reject the null hypothesis. Among those with rejection, only 77 recipients had a grade of acute rejection greater than borderline. Interestingly, in the group of recipients with no rejection during the follow-up period where the sample size was considerably greater, the presence of increased familial aggregation was convincingly demonstrated (Table 2) . This study was designed as a pilot project and we did not perform a power calculation due to the fact that we had a sample size that was limited by the uniqueness of the UPDP and therefore could not be expanded even if the sample size was deemed to be insufficient. While the calculation of the sample size is similar to that for other case-control studies, the effect size of the GIF is difficult to assume as no preliminary data are available. This project in fact might serve as pilot results for the future more definitive studies. A larger study, which would include all transplant recipients in the state of Utah (as opposed to those followed by the University of Utah), may potentially overcome this limitation.
Also, as the population of Utah is racially homogeneous and predominantly represented by the patients of Northern European descent, the generalizability of the study might potentially be limited to this population. In addition, the study included patients transplanted in different transplant eras. While the immunosuppressive protocols were changing over years, factors causing acute rejection might also be different between early years of transplantation and more recent eras. Due to the limited sample size, we did not stratify analysis based on the transplant era. However, while the rate of rejection might be different in different transplant eras, changes in clinical practice should not affect the degree of relatedness between the subjects, measured by GIF; therefore, transplant era should not confound the results of the study.
Another potential drawback of this study is the potential misclassification bias. This might be due to under-reporting of acute rejection and also due to insufficient duration of the follow-up period. We do not believe that cases of unrecognized clinical rejection in this population were very likely, since patients were followed very closely. However, despite a very meticulous record review from different sources, it is theoretically possible that some cases of acute rejection were undocumented. That potential bias would reduce the effect size of the difference between the cases and controls. Prospective study might adequately address these issues, although it might be challenging and time consuming.
Also, using censored data for this analysis is a potential problem. The minimal duration of the follow-up in this study was 1 year (though most of the recipients were followed for longer than 1 year); it is possible that recipients might have developed acute rejection after the completion of the study. While technically it is impossible to capture these 'potential rejectors', they contaminate the group of recipients with a rejection-free course, which might reduce the effect size and significance of the difference. Future studies with a longer follow-up may be necessary to include recipients with late rejection.
It is also probably important to discuss some of the issues with data analysis. Our analysis (GIF statistics) is not adjusted for covariates. It is true that, in addition to potential familial predisposition, numerous other clinical factors might affect rejection rates. The question then becomes: is familiality an independent factor relative to HLA match, cold ischaemic time or immunosuppression? In order to confound our assessment of the relationship between family history and transplant rejection, a variable must be associated with both the outcome (rejection) and the exposure (family history), without being an intermediate outcome. There is little reason to think that cold ischaemia time could be associated with family history. On the other hand, both immunosuppression and HLA types (hence the likelihood of a good match) might be intermediate outcomes, and statistical adjustment for these would not be appropriate.
Specific to this dataset, the groups of recipients with and without rejection are somewhat different (Table 1) , which might confound the results of this study because of ESRD, as some diseases have a stronger genetic component than the others. However, the distribution of the diseases with a strong genetic component (e.g. polycystic kidney disease, Alport's syndrome) was not much different. In addition, the authors are not aware of reported data where the association between primary kidney disease and acute rejection would have been convincingly demonstrated. Therefore, while analysis was not adjusted for the cause of ESRD, the distortion of the results by confounding is not very likely. Finally, confounding by the factors not studied in this project is possible; in particular, compliance level might theoretically be similar in the members of the same family. In that regard, any potential environmental factor(s) to which the families were exposed might theoretically explain the familial aggregation of the outcome. To that end, in this study we have not claimed to establish the genetic component of acute rejection; instead we studied the hypothesis that having rejection or having rejection-free post-transplant course might have a higher than expected degree of familiality. It is important to emphasize, that familial aggregation of acute rejection does not necessarily mean the presence of underlying genetic determinants. In fact, families living together might be exposed to a common environment. Generally, it is more likely that the first-degree relatives live in close proximity or together, as opposed to distant relatives. In general, the fact that familial aggregation is present in distant relatives argues towards the effect of genetic rather than environmental factors. An indication that genetic factors might actually play an important role is in the fact that not only close, but also very distant relatives, who are unlikely to be exposed to the same environment, were included in the study. In this study, we did not have information on the living conditions or which subjects might belong to the same household or live in close proximity. Therefore, we were very careful not to claim the presence of genetic predisposition to acute rejection, but only familial aggregation of this condition, which may be explained by both genetic factors and common environment that families are exposed to.
The notion that genetic factors might indeed have an association with acute rejection might have serious implications for personalized medicine in the future. The focus of other researchers was primarily on the areas associated with inflammation and immune response [24] . Prior efforts were mostly based on candidate gene analysis, while genomewide association studies have not been performed, possibly due to the difficulties associated with an adequate number of samples for a meaningful study [24] . If such genetic determinants are established in the future, their role in other organ transplants might also be evaluated. While it is exciting to hypothesize about such possibilities and their implications for healthcare and personalized medicine, change in clinical practice might require more research and therefore might not necessarily be possible in the immediate future.
In conclusion, there is a familial (though not necessarily genetic) component to rejection-free transplant course and trend to familial aggregation in recipients with acute rejection of grade 1A or higher. Future genetic studies might be necessary to identify potential regions of the genome associated with acute rejection. If a genetic association study is performed, there are families in Utah identified in the current study that can be targeted to increase the power of the test.
